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Abstract
Background: Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence,
characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape
of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose mechanism of action relies on
the killing of CD22 positive leukemic cells, through the delivery, after cell binding, of a molecule of calicheamicin.
Case presentation: We report two cases of CD22 positive relapsed EM-ALL treated with IO, obtained as
compassionate use. Case 1, a 66 years old woman, affected by Philadelphia (Ph) negative B-ALL, relapsed with
extramedullary involvement after 6 standard chemotherapy courses, who reached a complete metabolic
response with IO treatment. Case 2, a 67 years old man with Ph positive B-ALL, initially treated with ponatinib, a third
generation tyrosine-kinase inhibitor (TKI), obtaining a prolonged deep molecular remission. Nevertheless, for skin
relapse during TKI treatment, the patient received local radiotherapy and, shortly after, standard chemotherapy, as
multiple abdominal sites of relapse were detected too, with no response. The patient then received IO, obtained as
compassionate use, with a good metabolic response.
Conclusions: These two cases suggest a possible key role of IO in the setting of advanced CD22 positive ALL, and
underline its potential activity also in patients with EM involvement, relapsed after or refractory to conventional
chemotherapy. Despite the well known hepatotoxic effect of the compound (Sinusoid Occlusive Syndrome), neither of
them had such adverse event, moreover the second patient safely underwent allogeneic bone marrow transplantation.
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Background
Salvage therapy of relapsed/refractory (R/R) B-cell
Acute Lymphoblastic Leukemia (ALL) remains an un-
solved issue [1]. Aside standard chemotherapy, which
is the best treatment choice between blinatumomab,
CAR-T cells and IO, that currently represent the most
promising therapeutic options? [2] To the best of our
knowledge, there are no shared guidelines on the
management of R/R B-ALL, even more considering
the particular setting of EM disease. On one hand,
despite the impressive activity demonstrated in the
setting of Minimal Residual Disease (MRD) positive
ALL patients, blinatumomab seems to be less effective
in the context of EM involvement [3]. On the other
hand, the recent clinical trials assessing the role of IO
in R/R patients did not specifically focus on EM dis-
ease. Therefore, the investigation of the role of IO in
patients with such a poor prognosis is strongly
required.
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Case presentation
Case1
A 66 years old woman, presenting increasing asthenia,
revealed at peripheral blood count a severe anemia (Hb
7.3 g/dL), a reduced white blood cell (WBC) count
(2400/μL) with severe neutropenia (neutrophils 600/μL),
and a normal platelet count (PLT 168.000/μL). The diag-
nostic work-up showed a B-ALL, with normal karyotype,
negative for BCR-ABL rearrangement and with imma-
ture B-cell origin (CD19+, CD22+, SMIg+, TdT+,
CD20-). The CT-scan performed at diagnosis revealed a
solid-lesion (7.0 cm width) at the right kidney’s inferior
pole, that turned out to be a clear cell carcinoma (surgi-
cally removed later). The patient received 6 courses of
chemotherapy according to BFM schedule, following
local Institutional guidelines, including monthly intra-
thecal central nervous system (CNS) prophylaxis. After
the first chemotherapy cycle, she reached a morphologic
complete remission (CR) with MRD negativity, evaluated
by analysis of clonal rearrangement of IgH gene study
(according to Biomed EuroMRD Protocol [4]). Such a
deep response was confirmed and maintained during all
the six courses of chemotherapy.
After about 1 year and a half of sustained MRD nega-
tivity, blasts were documented at the peripheral blood
smear. She performed a 18F-PET/CT (PET-CT), consid-
ering the recent history of renal cancer, that documented
the presence of multiple lesions (Fig. 1a and d) [5],
including a large pancreatic one. In order to define the
following therapeutic approach, a differential diagnosis
between renal cancer metastasis and EM-ALL
localization was required. A pancreatic eco-endoscopic
biopsy was performed, revealing a population of CD19+
and CD22+ lymphoid cells (Fig. 1g,h). Blast cells’ CD22
positivity suggested an approach with IO, which was ob-
tained as compassionate use. IO was administered
weekly in hospitalized regimen, for a total of three infu-
sions (1,3 mg on day 1; 0,8 mg on day 8 and 15). Ther-
apy was well tolerated, and no adverse events occurred.
As expected, the bone marrow evaluation showed a
morphologic CR, even with MRD positivity (10-3). EM
disease was still present, though, as detected by a
PET-CT scan, which showed a slight reduction of the
pancreatic lesion previously reported, with the onset of
new hypermetabolic areas (Fig. 1b, e). Nevertheless, a
second course of weekly IO was administered, for a total
of four infusions (0.8 mg per dose). Surprisingly, the
further PET-CT-scan documented a complete metabolic
response (CMR) (Fig. 1c, f ) associated with bone mar-
row MRD negativity. Currently, the patient is in good
clinical conditions and still on IO (course 4), waiting for
the identification of a matched-unrelated donor, not yet
available, to proceed to allogenic bone marrow trans-
plantation (allo-BMT).
Case2
A 67 years old man, suddenly presented muco-cutaneous
bleedings associated with severe thrombocytopenia (PLT
13.000/μL), mild anemia (Hb 8.3 g/dL) and marked hyper-
leukocytosis (WBC 63.000/μL, 93% blast cells). The bone
marrow examination showed a remarkable lymphoblast
infiltration (TdT+, CD79a+, CD22+, CD19). Conventional
cytogenetic analysis revealed t(9;22). Therefore, the diag-
nosis of BCR-ABL1 (p190)-positive B-ALL was made. The
patient received a 7-day steroid pre-phase followed by
ponatinib (Iclusig) at the initial dose of 15 mg daily,
rapidly increased to standard dosage, 45 mg/daily,
associated with monthly medicated lumbar punctures
(methotrexate, cytarabine and dexamethasone), according
to the GIMEMA LAL1811 clinical trial (NCT01641107).
He obtained a morphological CR after 10 days of ponati-
nib, while MRD evaluated by real-time PCR never reached
values below 0.003 copies (assessed by BCR-ABL/ABL
ratio). Therapy was well tolerated and continued for
18 months, until the patient presented a painless skin
lesion on the forehead, that turned out to be a CD19+
CD22+ EM-ALL localization. Bone marrow was still nega-
tive for leukemic infiltration. After local radiotherapy
(4000 cGy) the skin lesion completely resolved, but
the PET-CT scan control, performed just 2 months
later, revealed multiple new hypermetabolic thoracic
and abdominal lesions. Therefore, the patient received
two courses of chemotherapy, according to BFM
schedule. Therapy was complicated by an episode of
gastrointestinal bleeding (melena with severe anemia)
caused by duodenal and gastric disease localizations,
documented bioptically (Fig. 2d-f ). The PET-CT scan
after the chemotherapy courses (Fig. 2a) showed a re-
markable disease progression (PD). Immunohisto-
chemistry of duodenal biopsy had showed CD22
positivity, suggesting a possible efficacy of IO therapy,
obtained as compassionate use. He underwent two IO
courses according to standard schedule without the
occurrence of any adverse event. The following bone
marrow analysis documented a persistent morpho-
logical and cytogenetic CR, but still MRD positivity
(BCR-ABL/ABL 0.03 copies). The PET-CT scan
showed the progressive decrease of all previously de-
scribed lesions (Fig. 2b, c), reaching a partial meta-
bolic response (PMR), because of the persistence of a
pathologic hypermethabolic areola. The patient pro-
ceeded to allo-BMT 1 month later. No GVHD oc-
curred, and no VOD/SOS (Veno-occlusive disease/
Sinusoidal occlusive syndrome) was observed. To sum
up, the patient had several EM “outbreak” relapses,
while the bone marrow morphologic complete remis-
sion with MRD positivity was maintained. None of
the therapies he underwent (TKI, local radiotherapy,
chemotherapy, IO) lead to MRD negativity. However,
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notably, only IO induced an important reduction of
extramedullary disease localizations.
Discussion and conclusion
Thanks to its good safety profile and a wide experience
in clinical practice, blinatumomab is currently consid-
ered the first therapeutic choice in R/R Ph- ALL [6, 7].
However, there are at least two still-open issues about its
effectiveness: the occurrence of CD19- immune escape,
and its poor effect on EM disease. Firstly, loss of CD19
has been demonstrated to represent a key element of re-
sistance [3]. Splice variants, point mutations, lineage
switch, CD81 deficiency are some of the better described
CD19- relapse mechanisms [8–11]. Moreover, as re-
cently reported, a high count of T reg lymphocytes, and
an impaired T reg/ T eff ratio, have been described to be
predictive for blinatumomab resistance, mainly due to
interleukin-10 production, resulting in suppression of
T-cell proliferation and reduced CD8-mediated lysis of
ALL cells [12]. Secondly, to the best of our knowledge,
studies investigating or explaining the low efficacy on
EM disease are still lacking.
Furthermore, Aldoss et al. suggested that a previous
history of EM disease localization before blinatumomab
administration predicts a lower CR rate (p < 0.05), EM
relapse, and progression during therapy. One of the
most interesting findings was that, in about 20% (5/32)
Fig. 1 Imaging and Histological analysis from Case 1 patient: (a) MIP image (PET-CT scan) before the beginning of IO treatment showing multiple
areas of pathological hypermetabolism at patient’s skeleton, spleen and pancreas (SUV max = 32); (b) MIP image (PET-CT scan) after the first
course of IO showing the disappearance of the diffuse uptake at patient’s skeleton, a slight reduction of the pancreatic lesion previously reported,
with the onset of new areas of pathological uptake within pancreas, gastric fundus and antrum and left renal parenchyma (Deauville V – Progressive
Disease); (c) MIP image (PET-CT scan) after the second and last IO course showing a complete metabolic response (Deauville I), with the disappearance
of all the previously described lesions; (d) Axial section of a PET-CT scan performed before IO treatments showing pathologic hypermetabolism in
pancreas head and body (SUV max = 32, Deauville V), spleen and skeleton (Deauville IV); (e) Axial section of a PET-CT scan performed after the first IO
course showing a Progression of the Disease; (f) Axial section of a PET-CT scan performed after the second and last course of IO documenting a
Complete Response. (g) Histological image from a Pancreatic echo-endoscopic biopsy showing pancreatic exocrine tubulo-acinar secretory units with
massive infiltration represented by B-ALL neoplastic cells (Light Microscopy, Wright-Giemsa); (h) Histological image from a Pancreatic echo-endoscopic
biopsy with specific immunostaining showing CD22 slight positivity of B-ALL blasts (Light Microscopy)
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of non-responders, a marrow CR with evidence of simul-
taneous leukemia progression in EM sites was docu-
mented [3].
On the other hand, IO has shown similar CR and
Overall Survival (OS) rates with a different safety pro-
file [13, 14]. A phase III randomized study (INO-VATE)
demonstrated the superiority of IO compared to stand-
ard chemotherapy in terms of CR rates, underlining the
potential role of the drug as a bridge-to-transplant op-
tion [15]. IO consists of a toxin (calicheamicin) conju-
gated to an anti-CD22 antibody [2], which allows its
delivery to blast cells; hence, its toxicity does not seem
to involve immune cells and, differently from what re-
ported concerning blinatumomab, no cases of CD22
antigen loss have been described so far. Moreover,
lineage switch mechanism (myeloid conversion), de-
scribed mostly in CAR-T cell therapy, does not seem
to involve CD22 expression: the antigen is maintained
on the intermediate phenotype relapses, suggesting
that simultaneous pressure on CD19 and CD22 might
avoid this resistance mechanism [13]. Although ex-
perimental studies have not specifically evaluated the
effectiveness of IO on EM disease, its mechanism of
action suggests that EM-lesion’s microenvironment
and resident cell subpopulations may have a more
negative influence on blinatumomab than on IO
effectiveness.
These case reports, coming from our single-center ex-
perience (totally 17 patients treated with IO) described the
use of IO in EM-ALL relapses in two different settings. In
both cases IO was the therapeutic choice, based on CD22
positivity assessed by immunohistochemistry on EM-lesion
biopsy (Figs. 1g, h, 2d-f). Both patients achieved a bone
marrow CR (Case 1 MRD negativity too) and a significant
resolution of the EM involvement (1 CMR and 1 PMR),
allowing them to be eligible for allo-BMT.
In conclusion, despite the mild effect of immunotherapy
(blinatumomab and CAR-T) on EM disease localizations
has been widely described in cancer, we hypothesize that
IO could represent a valid and promising therapeutic
choice in this particular and dismal setting. Moreover, we
suggest the assessment of CD22 status at diagnosis and re-
lapse in all B-ALL patients, in order to better evaluate the
indication for IO use. Further studies are strongly needed
to confirm our hypothesis.
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Fig. 2 Imaging and Histological analysis from Case 2 patient: (a) MIP image (PET-CT scan) performed before the beginning of IO showing an
multiple areas of pathological uptake localized at mediastinum, pectoral, axillary, gastric, mesenteric and iliac region (SUV max = 7.7); (b) MIP
image (PET-CT scan) performed after the first course of IO showing a reduction of almost all the previously detected lesions, considered a Partial
Metabolic Response (Deauville IV); (c) MIP image (PET-CT scan) performed after the second and last IO course showing the resolution of all the
previously described lesions, with the persistence of slight pathological uptake next to the gastric great curvature and the hepatic hilus (SUV max = 4,
Deauville IV); (d) Histological image from a duodenal biopsy documenting the epithelial surface of intestinal villa and submucosa diffusely infiltrated by
blasts cell (Light Microscopy, H&E); (e) Histological image from a Duodenal biopsy showing the duodenal surface with the brush border on the
epithelium and the submucosal populations of B-ALL neoplastic cells (Light Microscopy, Wright-Giemsa); (f) Histological image from a Duodenal
biopsy with specific immunostaining showing CD22-positive B-ALL blasts (Light Microscopy)
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